Meeting
2021 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.
Authors
Jessica Jiyeong Lin
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Jessica Jiyeong Lin , Shivaani Kummar , Daniel Shao-Weng Tan , Ulrik Niels Lassen , Serge Leyvraz , Yongmei Liu , Victor Moreno , Jyoti D. Patel , Lee S. Rosen , Benjamin Maurice Solomon , Ricarda Norenberg , Laura Dima , Nicoletta Brega , Lin Shen , Alexander E. Drilon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02576431 and NCT02122913
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9109)
DOI
10.1200/JCO.2021.39.15_suppl.9109
Abstract #
9109
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.
First Author: Alexander E. Drilon
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
First Author: Jessica Jiyeong Lin
Poster
2023 ASCO Annual Meeting
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: David S. Hong
Poster
2023 ASCO Annual Meeting
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).
First Author: Maria E. Cabanillas